These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The Search for an Alternative to [ Waldmann CM; Stuparu AD; van Dam RM; Slavik R Theranostics; 2019; 9(5):1336-1347. PubMed ID: 30867834 [TBL] [Abstract][Full Text] [Related]
4. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033 [TBL] [Abstract][Full Text] [Related]
5. [ Hennrich U; Eder M Pharmaceuticals (Basel); 2021 Jul; 14(8):. PubMed ID: 34451810 [TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of [ Gaertner FC; Plum T; Kreppel B; Eppard E; Meisenheimer M; Strunk H; Bundschuh RA; Sinnes JP; Rösch F; Essler M Nucl Med Biol; 2019; 76-77():1-9. PubMed ID: 31520872 [TBL] [Abstract][Full Text] [Related]
7. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE. Velikyan I; Xu H; Nair M; Hall H Nucl Med Biol; 2012 Jul; 39(5):628-39. PubMed ID: 22336375 [TBL] [Abstract][Full Text] [Related]
8. Tumour-to-liver ratio determined by [ Kim YI; Yoo C; Oh SJ; Lee SJ; Kang J; Hwang HS; Hong SM; Ryoo BY; Ryu JS EJNMMI Res; 2020 Jun; 10(1):63. PubMed ID: 32542576 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1. Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103 [TBL] [Abstract][Full Text] [Related]
10. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle. Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350 [TBL] [Abstract][Full Text] [Related]
11. Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms. Adnan A; Basu S Diagnostics (Basel); 2023 Jun; 13(13):. PubMed ID: 37443548 [TBL] [Abstract][Full Text] [Related]
12. Instant kit preparation of Sinnes JP; Nagel J; Waldron BP; Maina T; Nock BA; Bergmann RK; Ullrich M; Pietzsch J; Bachmann M; Baum RP; Rösch F EJNMMI Res; 2019 May; 9(1):48. PubMed ID: 31123943 [TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and Biological Evaluation of Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911 [TBL] [Abstract][Full Text] [Related]
14. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism. Traub-Weidinger T; Putzer D; von Guggenberg E; Dobrozemsky G; Nilica B; Kendler D; Bale R; Virgolini IJ Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1995-2001. PubMed ID: 26173620 [TBL] [Abstract][Full Text] [Related]
15. Occupational radiation exposure assessment during the management of [ Riveira-Martin M; Struelens L; Schoonjans W; Sánchez-Díaz I; Muñoz Iglesias J; Ferreira Dávila Ó; Salvador Gómez FJ; Salgado Fernández M; López Medina A EJNMMI Phys; 2022 Oct; 9(1):75. PubMed ID: 36309605 [TBL] [Abstract][Full Text] [Related]